Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 16/20 | 0.48 |
| ▸ | ITGAV | P06756 | 16/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4641533 | 0.92 | ITGB3 (0.42) | ITGB3ITGAVMAPTKDRRET | |
| SCHEMBL6807080 | 0.86 | ITGB3 (0.40) | ITGB3ITGAV | |
| SCHEMBL6806739 | 0.84 | ITGB3 (0.40) | ITGB3ITGAVMAPTKDRRET | |
| SCHEMBL7060984 | 0.80 | MAPT (0.37) | ITGB3ITGAVMAPTKDRRET | |
| SCHEMBL4640795 | 0.77 | SLC29A1 (0.38) | ITGB3ITGAVMAPT | |
| SCHEMBL5840142 | 0.75 | HDAC6 (0.47) | ITGB3ITGAV | |
| SCHEMBL4641283 | 0.74 | ITGB3 (0.46) | ITGB3ITGAV | |
| SCHEMBL4640793 | 0.73 | ITGB3 (0.47) | ITGB3ITGAV | |
| SCHEMBL4640796 | 0.73 | ITGB3 (0.47) | ITGB3ITGAV | |
| SCHEMBL6804204 | 0.73 | ITGB3 (0.47) | ITGB3ITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0853084-B1 | Substituted purine derivatives as vitronectin receptor antagonists | HOECHST AG (DE) | 2008-08-13 | — | — | EP | disclosed |
| US-6723727-B1 | VITRONECTIN RECEPTOR ANTAGONISTS; INHIBITORS OF BONE RESORPTION; OSTEOPOROSIS | HOECHST AKTIENGESELLSCHAFT (DE) | 2004-04-20 | — | — | US | disclosed |
| US-20040063716-A1 | Cholesterol biosynthesis inhibitors containing as the active ingredient tricyclic spiro compounds | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-0853084-A2 | Substituted purine derivatives as vitronectin receptor antagonists | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-07-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063716-A1 | Cholesterol biosynthesis inhibitors containing as the active ingredient tricyclic spiro compounds | VKORC1, CYP46A1, TFPI | ITGB3 3138/4885ITGAV 2425/4885MAPT 4311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.